A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease

Exclusion Criteria

• •1. Unable to take multiple capsules orally.
• •2. Alcohol consumption of greater than an average of one drink per day for women and two drinks per day for men.
• •3. Hemochromatosis.
• •4. Hepatic encephalopathy.
• •5. Compromised immune system (e.g. primary immune disorders or clinical immunosuppression due to a medical condition or medication e.g. taking oral prednisone \>20 mg a day or prednisone-equivalent)
• •6. Receipt of systemic non-topical antibiotic therapy within 14 days of treatment day 1.
• •7. History of use of an investigational drug within 90 days prior to the screening visit.
• •8. Positive results for active HIV, Hepatitis B, or Hepatitis C infections.
• •9. Current history for active states of Inflammatory bowel disease, Irritable bowel syndrome, microscopic colitis, celiac disease, short gut syndrome, colostomy, colectomy, gastrointestinal fistulae or strictures.
• •10. History of significant uncontrolled systemic disease that in the opinion of the study investigator could interfere with study participation and/or objectives.
• •11. Life expectancy of \< 1 year.
• •12. In the opinion of investigator, subject for any reason, should be excluded from the study.